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Reply
We appreciate the letter discussing the importance of high-density
lipoprotein (HDL) in the pathogenesis of aortic valve disease. We
agree with the author that there are many mechanisms involved in
aortic stenosis. The work of Dr. Otto was the first to define the
atherosclerotic risk factors in the development of calcific aortic
stenosis (1). This important study set up the hypothesis that
calcific aortic stenosis is an active biologic disease.
Since then, there have been a number of experimental models
implicating the potential mechanisms by which calcification de-
velops. The primary hypothesis has been proposed by Rajamannan
et al. (2) and Mohler et al. (3), that an active osteoblast bone
formation is present in the calcifying aortic valve. The field of
valvular heart disease is now poised for large-scale clinical trials to
define the pharmacologic targets for this disease process. Our
design for the RAAVE (Rosuvastatin Affecting Aortic Valve
Endothelium) trial (4) was to test the effect of low-density
lipoprotein (LDL) lowering in the treatment of aortic valve
stenosis. We designed the trial and powered the statistical analysis
in terms of LDL lowering and echocardiographic monitoring. In
the study by Yilmaz et al. (5), they demonstrated the importance
of HDL and its predictive value in treating aortic valve disease.
However, that study was published after the initiation of the
RAAVE trial, and therefore the importance of HDL was not
emphasized in our final analysis. However, HDL is an important
predictor and we plan to perform a subanalysis.
Calcific aortic stenosis has been a surgical disease for the past 40
years since the landmark 1968 paper of Ross and Braunwald (6)
defined surgical valve replacement at the onset of symptoms. The
RAAVE trial (4) is the first trial of medical therapy to demonstrate
prospectively that LDL lowering and improvement in inflamma-
tory markers slow the progression of this disease. The issues that
will need to be considered are not only the effect of increasing
HDL and lowering LDL, but also the cellular biology of this
disease. Future clinical trials will need to take into account all of
these aspects in their design.
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